Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aurinia Pharmaceuticals Q2 2024 GAAP EPS $0.01, Inline, Sales $57.200M Beat $55.055M Estimate

Author: Benzinga Newsdesk | August 01, 2024 06:02am
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. The company reported quarterly sales of $57.200 million which beat the analyst consensus estimate of $55.055 million by 3.90 percent. This is a 37.85 percent increase over sales of $41.494 million the same period last year.

Posted In: AUPH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist